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The influence of systemic inflammation, dietary intake and stage of
disease on rate of weight loss in patients with gastro-oesophageal
cancer
DAC Deans1, BH Tan1, SJ Wigmore1, JA Ross1, AC de Beaux1, S Paterson-Brown1 and KCH Fearon*,1
1University Department of Surgery, Royal Inf irmary, 51 Little France Crescent, Old Dalkeith Road, Edinburgh EH16 4SA, UK
Although weight loss is often a dominant symptom in patients with upper gastrointestinal malignancy, there is a lack of objective
evidence describing changes in nutritional status and potential associations between weight loss, food intake, markers of systemic
inflammation and stage of disease in such patients. Two hundred and twenty patients diagnosed with gastric/oesophageal cancer
were studied. Patients underwent nutritional assessment consisting of calculation of body mass index, measurement of weight loss,
dysphagia scoring and estimation of dietary intake. Serum acute-phase protein concentrations were determined by enzyme-linked
immunosorbent assay. In all, 182 (83%) patients had lost weight at diagnosis (median loss, 7% body weight). Weight loss was
associated with poor performance status, advanced disease stage, dysphagia, reduced dietary intake and elevated serum C-reactive
protein (CRP) concentrations. Multiple regression identified dietary intake (estimate of effect, 38%), serum CRP concentrations
(estimate of effect, 34%) and stage of disease (estimate of effect, 28%) as independent variables in determining degree of weight loss.
Mechanisms other than reduced dietary intake or mechanical obstruction by the tumour appear to be involved in the nutritional
decline in patients with gastro-oesophageal malignancy. Recognition that systemic inflammation plays a role in nutritional depletion
may inform the development of appropriate therapeutic strategies to ameliorate weight loss, making patients more tolerant of
cancer-modifying treatments such as chemotherapy.
British Journal of Cancer (2009) 100, 63 – 69. doi:10.1038/sj.bjc.6604828 www.bjcancer.com
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Cachexia remains an important cause of morbidity and mortality
among cancer patients, affecting up to 85% of patients with
gastrointestinal malignancy at the time of diagnosis (Alexandrakis
et al, 2003). Cancer cachexia is associated with reduced quality of
life scores, reduced performance status, lower response rates to
chemotherapy and overall poorer outcomes (DeWys et al, 1980;
Ross et al, 2004; Barber et al, 1999a). Around 20% of deaths from
cancer may be directly related to cachexia (Studley, 1936; Inagaki
et al, 1974). In a large study of patients with oesophageal cancer,
weight loss greater than 10% pre-morbid weight was the only
significant predictor of early death in patients undergoing surgical
resection (Kelson et al, 1998).
The weight loss that is commonly associated with gastro-
oesophageal malignancy is generally assumed to be secondary to
the mechanical effects of the tumour on the upper digestive tract.
Obstruction to swallowing, early satiety, nausea and vomiting are
common symptoms associated with these tumours. However, some
of these patients may remain relatively weight stable whereas other
patients show marked and rapid weight loss despite apparent
similarities in the degree of dysphagia and stage of disease. In
addition, weight loss and cachexia are commonly associated with
types of cancer not directly involving the gastrointestinal tract,
such as non-small cell lung cancer (Scott et al, 2002). A possible
explanation for these variations in nutritional status may relate to
the co-existence of systemic inflammation. Up to 50% of patients
with cancer have an acute-phase protein response (APPR) at the
time of diagnosis, including patients with upper gastrointestinal
malignancy (Falconer et al, 1994, 1995; Chen et al, 1999; Barber
et al, 1999b; Alexandrakis et al, 2003). Elevated acute-phase
protein concentrations have earlier been linked with increased
weight loss among patients with cancer. Elevated serum C-reactive
protein (CRP) concentrations have been correlated positively with
weight loss in human cancer patients (Falconer et al, 1995;
Wigmore et al, 1997; O’Gorman et al, 1999). An APPR in
pancreatic cancer patients is associated with elevated resting-
energy expenditure (REE) and reduced energy intake (Falconer
et al, 1994; Wigmore et al, 1997). In patients with cancer, therefore,
an APPR has been associated with hypermetabolism, anorexia,
increased weight loss and adverse prognosis (Argiles et al, 1997).
The clinical sequelae of systemic inflammation include altera-
tions in protein and fat metabolism, changes in energy expenditure
and alterations in patterns of hormonal secretion (Selby et al, 1987;
Baumann and Gauldie, 1994; Stouthard et al, 1995; Baracos et al,
2003). These metabolic changes may underpin the syndrome of
cachexia and may in part be mediated through increased
pro-inflammatory cytokine activity. Circulating concentrations of
IL-1b, IL-6 and TNFa and other cytokines have been associated
with anorexia and weight loss in rodent tumour models and inRevised 5 November 2008; accepted 21 November 2008
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human participants (Gelin et al, 1991; Strassmann et al, 1992).
More recently, IL-6 overexpression in the serum and in tumour
specimens of pancreatic cancer patients has been linked with
accelerated weight loss (Martignoni et al, 2005). Therefore, in
patients with cancer, the underlying metabolic alterations asso-
ciated with systemic inflammation may contribute to the develop-
ment of weight loss and cachexia in these patients.
This study describes the changes in nutritional status in a cohort
of patients with gastro-oesophageal cancer at the time of diagnosis
and investigates the contribution of systemic inflammation to their
nutritional decline.
MATERIALS AND METHODS
Study population
All patients diagnosed with gastric or oesophageal cancer within
the Lothian and Borders regions between March 2002 and June
2004 were eligible for inclusion into the study. No patients were
excluded and patients were recruited to the study within 2 weeks of
the time of diagnosis. All participants provided written informed
consent and the study received ethical permission from the
Lothian Research Ethics Committee. Every patient underwent an
assessment of his/her nutritional status at recruitment and blood
was collected at the same time for determination of serum acute-
phase protein concentrations. Patients were staged and underwent
various treatments following discussion at the multidisciplinary
team meeting. Duration of survival, defined from time of
histological diagnosis to death, was recorded for each patient.
Nutritional assessment
All patients underwent an assessment of their nutritional status at
the time of diagnosis. This involved calculation of body mass index
(BMI) and estimation of weight loss. Dietary intake was estimated
by patients and was validated in a subgroup of patients using
detailed food diaries. The severity of dysphagia was also assessed
and documented.
Calculation of BMI and rate of weight loss
Patients were evaluated for height with a stadiometre and weight
on spring balance scales, wearing light clothing, without shoes.
Patient recall, verified if possible from medical records, was used
to determine pre-morbid weight. Pre-morbid weight was recorded
in the medical case notes for 103 (47%) patients who had attended
an outpatient appointment and had been weighed in the previous
12 months. Body mass index and percentage weight loss compared
with pre-morbid weight were calculated. Rate of weight loss was
defined as the total amount of weight lost by the patient divided by
the number of months of symptoms experienced by the patient.
This was chosen as the arbitrary definition of rate of weight loss to
gain some information on the rate of weight loss for each patient.
Estimation of dietary intake and assessment of dysphagia
Dietary intake was estimated by all patients and scored as
1¼ normal, 2¼ reduced and 3¼ poor/minimal. This simple
assessment of dietary intake was validated in a subgroup of
patients using detailed food diaries. Patients (n¼ 22) were
instructed to record all food and drink consumed over a 3-day
period, which included a weekend day, and the data were analysed
by a senior dietician who provided information on the level of
intake of macronutrients using computer software (CompEats,
Nutrition Systems, Grantham, UK). Comparisons were made to
dietary reference values issued by the Department of Health
(1991).
The severity of dysphagia was assessed by interview and was
scored according to Knyrim et al (1993).
Determination of serum acute-phase protein
concentrations
Blood was collected from every patient at the time of diagnosis and
before any therapeutic intervention. All patients were free from
infection at the time of blood collection as determined by clinical
assessment. C-reactive protein, haptoglobin, a1-antichymotrypsin
(ACT), albumin and transferrin were selected as the acute-phase
proteins for investigation. C-reactive protein, haptoglobin and
ACT represent positive acute-phase proteins and albumin and
transferrin represent negative acute-phase reactants.
Serum CRP concentration was measured using an automated
immunoturbidimetric assay within the Clinical Biochemistry
Department, Edinburgh Royal Infirmary, UK. This method is a
high-sensitivity assay with a lower limit of detection of 0.2 mg l1.
Using this assay, a concentration of 10 mg l1 represents the upper
limit of the normal range, with most healthy individuals having a
serum concentration o2 mg l1 (Gabay and Kushner, 1999). The
coefficient of variation was less than 3%. Serum albumin
concentration was measured by the automated bromocresol green
dye-binding technique also in the Clinical Biochemistry
Department. Normal serum concentrations are 35–50 g l1. The
coefficient of variation was less than 3%.
Serum concentrations of haptoglobin, ACT and transferrin were
determined by sandwich enzyme-linked immunosorbent assay as
described earlier (Wigmore et al, 2002). The lower limit of
sensitivity for each assay was 100 pg ml1 for haptoglobin
(coefficient of variation o10%), 50 pg ml1 for ACT (coefficient
of variation o10%) and 30 pg ml1 for transferrin (coefficient of
variation o10%).
Statistical analysis
Non-parametric analysis was performed in all instances. Correla-
tions were investigated by Spearman’s rank test. Independent
variables were analysed by the Mann–Whitney U- or the Kruskal–
Wallis test. Categorical data were analysed by the w2-test. Receiver
operator characteristic (ROC) curves were used to evaluate the
ability of serum acute-phase protein concentrations to identify
patients with the fastest rate of weight loss. Multiple regression
modelling was used to identify the variables that were indepen-
dently associated with weight loss and to calculate the estimates of
size of effect.
RESULTS
Study patients
Group demographics are presented in Table 1. In summary, 220
patients were studied over a 28-month period. Ninety-five (43%)
patients underwent surgical resection and 25 of these received
pre-operative chemotherapy. In all, 7 (3%) patients received
chemoirradiation with curative intent. The remaining 118 patients
(54%) were not suitable for curative therapy and received palliative
treatment, such as chemotherapy or endoscopic stenting.
One-third (34%) of patients had metastatic disease (stage IV) at
the time of presentation and most other patients (n¼ 86; 39%) had
locally advanced (stage III) disease at diagnosis. About one-quarter
(n¼ 59; 27%) of patients had early-stage disease (stage I/II).
Patients were followed up for an average of 32 months and
minimum of 18 months (range, 18–45 months). At the time of
censoring the data, 147 (67%) patients had died. Overall median
survival was 13 months.
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Assessment of nutritional status
Weight loss The nutritional variables for the patient group
measured at the time of diagnosis are also shown in Table 1.
Patients had lost a median of 7.1% (inter-quartile range,
1.2–14.2%) of their total body weight at the time of diagnosis
compared with their pre-morbid stable body weight. This was
equivalent to a median rate of weight loss of 2.5% total body
weight per month of illness (inter-quartile range, 0.3– 6.5% per
month) (defined from the onset of symptoms). Only 38 (17%)
patients remained weight steady at the time of diagnosis, whereas
85 (39%) patients had lost more than 10% of their body weight.
Assessment of dietary intake and dysphagia Eighty-five (39%)
patients described their dietary intake as normal, 103 (47%)
patients described their intake as reduced compared with normal
and 32 (14%) patients had a poor or minimal food intake at
diagnosis. Assessment of dietary intake was validated in a
subgroup of patients (n¼ 22) using detailed food diaries, where
actual food intake was compared with perceived food intake. For
this patient subgroup, the median energy intake was
2027 kcal day1 (inter-quartile range, 1415–2228 kcal day1) and
the median protein intake was 72 g day1 (range, 58–92 g day1).
Absolute values were normalised to the estimated average
requirement for energy intake and to the reference nutritional
intake for protein intake (Table 1). Patient perception of reduced
food intake was associated with reduced total calorie intake and
reduced protein intake (P¼ 0.040 and 0.003, respectively; Mann–
Whitney U-test) (data not shown).
Reduced dietary intake was associated with a lower BMI at
diagnosis (P¼ 0.007, Kruskal–Wallis test), increased total weight
loss (Po0.001) and increased rate of weight loss (Po0.001).
In addition, reduced food intake was associated with reduced
Karnofsky performance scores (Po0.001, Kruskal –Wallis test)
and increased dysphagia scores (Po0.001, w2-test).
Eighty-nine (40%) patients had no dysphagia at diagnosis, 95
(43%) were able to swallow solid or semisolid food, 32 (15%) were
able to swallow liquids only and 4 (2%) patients had total
dysphagia. Increasing dysphagia was also linked with increased
weight loss.
Relationship between patient clinicopathological
characteristics and nutritional status
Oesophageal tumours were associated with higher dysphagia
scores (Po0.001, w2-test), but not with reduced dietary intake
(P¼ 0.612) or increased weight loss (P¼ 0.320). Total weight loss
was similar between the different histological subtypes (P¼ 0.206).
Advanced disease stage at the time of diagnosis was associated
with greater total weight loss (Po0.001), increased dysphagia
scores (Po0.001) and reduced dietary intake (Po0.001). Patients
with stage III and stage IV disease had lost a median 9.5% (inter-
quartile range, 4.3–16.0%) of their total body weight by the time of
Table 1 Patient demographics and nutritional variables at the time of
diagnosis (n¼ 220)
Number (%)
Age (years)a 71 (62–78)
Sex
Male 145 (66)
Female 75 (34)
Karnofsky score
30 4 (2)b
40 1 (1)
50 5 (2)
60 17 (8)
70 25 (12)
80 36 (17)
90 50 (24)
100 70 (34)
Unknown 12
Tumour site
Oesophageal 101 (46)
Proximal third 2
Middle third 13
Distal third 86
Oesophago-gastric junction 40 (18)
Gastric 79 (36)
Proximal 25
Body 26
Distal 28
Histology
Adenocarcinoma 185 (84)
Squamous cell carcinoma 30 (14)
Small cell 2 (1)
Indeterminate 3 (1)
Grade
Well differentiated 3 (2)b
Moderately differentiated 63 (34)
Poorly differentiated 118 (64)
Not commented 36
Subsequent treatment undertaken
Surgery alone 70 (32)
Pre-operative chemotherapy/surgery 25 (11)
Chemoradiotherapy with curative intent 7 (3)
Palliative chemotherapy 28 (13)
Palliative radiotherapy 6 (3)
Stent/dilatation/laser/symptomatic 84 (38)
UICC stage
1 25 (11)
2 34 (16)
3 86 (39)
4 75 (34)
Status
Alive 73 (33)
Dead 147 (67)
Pre-illness BMI 26.4 (24.1–30.1)
BMI at diagnosis 24.6 (21.4–28.0)
Total body weight loss (%) 7.1 (1.2–14.2)
Rate of weight loss (% per month) 2.5 (0.3–6.5)
Dietary intake
Normal 85 (39)
Reduced 103 (47)
Poor/minimal 32 (14)
Food diary intakec
Energy kcal (% of EAR) 87 (68–93)
Protein (% of RNI) 142 (109–170)
Table 1 (Continued )
Number (%)
Dysphagia score
0 89 (40)
1 52 (24)
2 43 (19)
3 32 (15)
4 4 (2)
BMI¼ body mass index; EAR¼ estimated average requirement; RNI¼ reference
nutritional intake (%). aValues are medians (inter-quartile range). bValues are
expressed as percentages of known results. cCalculated from a subgroup of 22
patients.
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diagnosis compared with patients with stage I and II disease
(median weight loss, 1.4%; inter-quartile range, 0 –7.3%).
Increased rate of weight loss from the time of diagnosis was
associated with adverse prognosis (Figure 1). The median survival
for patients in the tertile with the lowest rate of weight loss was
30.2 months; the median survival for those in the intermediate
weight-loss tertile was 10.2 months; and the median survival for
those patients with the fastest rate of weight loss was 7.5 months
(Po0.0001, log-rank test).
Relationship between markers of systemic inflammation
and nutritional status
Serum acute-phase protein concentrations The median CRP
concentration was 7 mg l1 (inter-quartile range, 2 –25 mg l1),
and at the time of diagnosis 121 (55%) patients had a CRP
concentration greater than 5 mg l1.
Serum markers of systemic inflammation and nutritional status Serum
acute-phase protein concentrations were associated with
nutritional variables. Elevated concentrations of the positive
acute-phase proteins (CRP, a1-antichymotrypsin and haptoglobin)
were associated with increased total weight loss and increased rates
of weight loss at the time of diagnosis, whereas the converse was
true for the negative acute-phase reactants (albumin and
transferrin). Serum CRP concentration was the best predictor of
rate of weight loss, as identified by an ROC curve (area under the
curve¼ 0.72 (Po0.001; 95% confidence interval 0.65– 0.79)). The
relationship between serum CRP concentration at diagnosis and
rate of weight loss is shown in Figure 2.
A cutoff value of 5 mg l1 was chosen to represent an elevated
serum CRP concentration. Patients were grouped into tertiles
according to the rate of weight loss; lowest tertile median rate of
weight loss¼ 0% per month (inter-quartile range, 0 –0.3% per
month), middle tertile median rate of weight loss¼ 2.4%
per month (inter-quartile range, 1.5–3.3% per month) and highest
tertile median rate of weight loss¼ 7.6% per month (inter-quartile
range, 6.4–14.5% per month). Increasing weight-loss tertile was
associated with elevated serum concentrations of CRP (Po0.001,
w2-test) (Table 2).
Multivariate analysis
Levels of dietary intake, dysphagia score, stage of disease,
treatment modality and serum acute-phase protein concentrations
(CRP) were all associated with rate of weight loss among the
patient group. Multiple regression analysis was performed to
identify the variables that were independently associated with
weight loss. Levels of dietary intake and dysphagia scores were
identified as confounding variables and, therefore, dietary intake
was retained in the multivariate analysis and dysphagia scores
were excluded. Similarly, stage of disease and treatment modality
were also confounding variables, and stage of disease alone was
analysed. Dietary intake (r¼ 0.28, Po0.001), stage of disease
(r¼ 0.19, P¼ 0.003) and serum CRP concentrations (r¼ 0.18,
P¼ 0.007) all retained independent association in determining the
extent of weight loss (Table 3). A multivariate general linear model
was then used to calculate the estimates of size of effect on degree
of weight loss for each variable (Table 3). These data suggested
that, overall, 38% of weight loss was determined by level of dietary
intake, 34% by serum CRP concentrations (systemic inflamma-
tion) and 28% was attributable to stage of disease.
DISCUSSION
This study has described the changes in nutritional status observed
at the time of diagnosis in a cohort of patients with gastro-
oesophageal cancer and has investigated the association between
these nutritional variables and markers of systemic inflammation.
At the time of diagnosis, patients with gastro-oesophageal cancer
show a median loss of 7% of their body weight at a rate of 2.5%
body weight loss per month. Eighty-three percent of patients had
Number at risk: 
Lowest tertile 73 58 39 18 3 
Middle tertile 73 38 21 7 1 
Highest tertile 74 32 19 6 0 
0.0 10.0 20.0 30.0 40.0
0.0
0.2
0.4
0.6
0.8
1.0
Figure 1 Survival curve representing survival duration in the patient
cohort from time of diagnosis stratified according to tertiles of rate of
weight loss. Thin line¼ lowest rate of weight-loss tertile with a median
survival of 30.2 months; middle line¼middle rate of weight-loss tertile with
a median survival of 10.2 months; thick line¼ highest rate of weight-loss
tertile with a median survival of 7.5 months (Po0.0001, log-rank test).
–6.00
–4.00
–2.00
0.00
2.00
4.00
0.00 1.00 2.00 3.00 4.00 5.00 6.00
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] 
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Figure 2 Scatter plot illustrating the positive correlation between
elevated serum CRP concentrations and rate of weight loss measured at
the time of diagnosis (Po0.001, r¼ 0.36; Spearman’s rank analysis). The
y-axis represents serum CRP concentrations in mg l1 and the x-axis
represents the percentage body weight lost per month of symptoms. Given
that the data are non-parametric, these values have undergone logarithmic
transformation.
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lost weight at the time of diagnosis. Increased weight loss was
associated with elevated serum acute-phase protein concentra-
tions. Weight loss was also associated with reduced dietary intake,
palliative treatment modalities and advanced stage of disease.
Multiple regression analysis identified level of dietary intake
(estimate of effect of size, 38%), serum CRP concentrations
(estimate of effect of size, 34%) and stage of disease (estimate of
effect of size, 28%) as independent variables in determining the
degree of weight loss.
Weight loss is common among patients with cancer, particularly
among patients with gastrointestinal malignancy in which up to
85% of patients may be affected during their illness (DeWys et al,
1980). One hundred and eighty-three (83%) patients in our study
had lost weight at the time of diagnosis with almost half of these
patients losing 10% or more of their pre-illness body weight.
Assuming a linear course, the median rate of weight loss was 2.5%
body weight per month (approximately 1.9 kg per month) and
compares with previous study relating to patients with pancreatic
cancer where the mean rate of weight loss was 2.3 kg per month
(Barber et al, 1999a; Fearon et al, 2003). Pancreatic cancer is
notorious for its association with marked weight loss (DeWys et al,
1980; Galizia et al, 2002).
Almost two-thirds (61%) of patients described their level of
dietary intake as reduced or poor compared with their normal
levels of intake and, not surprisingly, reduced dietary intake was
associated with increased total weight loss and increased rate of
weight loss. Recent studies have shown loss of appetite to be an
independent prognostic factor for survival in patients with gastro-
oesophageal cancer (McKernan et al, 2008). In this study, we found
that patients’ perception of their level of dietary intake reflected
actual levels of energy and protein intake as determined from
detailed food diaries. Diet diaries have been shown earlier to reflect
usual daily food intake, and it would appear that patients’
perception of their level of food intake may also reflect actual
levels of dietary intake (Bingham et al, 1982; Gibson, 1990). We
accept that recalled weight loss will be subjected to some error.
However, earlier studies have found a good correlation between
recalled stable weight and weight recorded in patients’ hospital
notes before their current illness. A study of Japanese men found
that weight recalled by patients strongly correlated with measured
weight (r¼ 0.849) (Tamakoshi et al, 2003). We also accept that the
main error in calculating rate of weight loss will come from the
duration of weight loss where the calculation is reliant on two
items of patient recall. Within these limitations, it is readily
possible to discriminate those who are weight stable from those
patients who lose weight rapidly. A further analysis involving the
use of detailed food diaries, along with possible body composition
analysis, would allow more detailed conclusions to be drawn and
should form the basis of future studies.
More than half (60%) of the patients had symptomatic
dysphagia at the time of diagnosis. Increasing dysphagia scores
were associated with increased total weight loss, increased rate of
weight loss and reduced levels of food intake. Patients with gastro-
oesophageal malignancy are not only subjected to the systemic
effects of the disease on their nutritional status (for example,
anorexia, hypermetabolism and altered protein metabolism), but
also affected by the local effects of the tumour on the upper
digestive tract. However, patients without dysphagia (and who had
a ‘normal’ level of food intake) had still lost a median 4.4% of their
total body weight by the time of diagnosis (rate, 1.5% per month)
and therefore the systemic influences of the cancer on nutritional
status remain important among these patients.
Table 2 Association between rate of weight loss, clinicopathological
variables and serum CRP concentrations (w2 analysis)
Rate of weight loss
(% body weight lost per month)
Lowest
tertile Mid tertile
Highest
tertile P-value
Agea 70 (64–77) 72 (62–77) 71 (62–78) 0.961
Sex
M 47 52 46 0.419
F 26 21 28
Tumour site
Oesophageal 36 30 35 0.320
OGJ 8 18 13
Gastric 29 25 27
Stage of disease
I 15 7 3 o0.001
II 21 9 3
III 20 31 37
IV 17 26 31
Treatment modality
Surgery alone 40 19 7 o0.001
Pre-operative
chemotherapy
and surgery
8 8 8
Chemoradiotherapy 8 16 17
Palliation 17 30 42
CRP (mg l1)
o5 45 33 21 o0.001
X5 28 40 53
Dietary intake
Normal 49 23 14 o0.001
Reduced 21 39 42
Poor/minimal 3 11 18
Dysphagia score
0 40 27 23 o0.001
1 23 16 11
2 7 15 21
3 2 13 17
4 0 2 2
CRP¼C-reactive protein. aMedian (inter-quartile range); Kruskal –Wallis test.
Table 3 Multiple regression analysis of variables associated with increased weight loss
Regression coefficient 95% confidence interval F-test
Estimates of effect
size (%) P-value
Dietary intake 0.28 0.87–2.44 1.9 38 o0.001
Stage of disease 0.19 0.24–1.34 0.9 28 0.003
CRP concentration (o5 or X5 mg l1) 0.18 0.40–2.54 1.3 34 0.007
CRP¼C-reactive protein. Dietary intake, stage of disease and serum CRP concentrations all retained independent associations in determining degree of weight loss.
A multivariate general linear model was then used to calculate the estimates of size of effect on degree of weight loss for each variable.
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Stage of disease was also identified as an important determinant
of rate of weight loss on multivariate analysis. Advanced disease
stage may represent a more aggressive tumour biological
behaviour with higher metabolic demands and a propensity for
increased cell turnover and energy consumption. In addition,
advanced disease stage may act as an indirect measure of tumour
burden, which may not only place increased metabolic demands
on the host, but may also result in increased production and
release of biological mediators, such as pro-inflammatory cyto-
kines and other tumour-derived products, that may contribute to
the altered metabolism that is associated with the syndrome of
cachexia. Increased size of the primary tumour has been linked
with elevated serum CRP concentrations in patients with operable
colorectal cancer, suggesting an association between tumour bulk
and the magnitude of the systemic inflammatory response (Crozier
et al, 2007).
Serum acute-phase protein concentrations correlated with total
weight loss and rate of weight loss. Earlier, a similar association
between elevated serum CRP concentrations and increased weight
loss in pancreatic cancer patients has been identified and other
groups have found similar associations in other cancer types
(Falconer et al, 1995; O’Gorman et al, 1999; Barber et al, 1999a;
Scott et al, 2002). In addition, REE in cancer patients is increased
compared with controls and those patients with an APPR have
greater REE compared with cancer patients without an APPR
(Falconer et al, 1994). Cancer patients with an APPR have been
shown to have elevated fibrinogen synthesis rates in both the fed
and fasting states, and it is this reprioritisation of protein
metabolism that accompanies the APPR that may also contribute
to the wasting observed in cancer cachexia (Preston et al, 1998;
Barber et al, 2000). In this study, CRP and albumin concentrations
were identified as the best predictors of rate of weight loss by ROC
curves. However, serum albumin concentrations may be influ-
enced by malnutrition, hydration status and trans-capillary escape,
as well as the presence of an inflammatory response (Fleck et al,
1985), and therefore serum CRP concentrations were chosen for
entry into the multivariate analysis.
Serum cytokine concentrations were not measured in this
study. The difficulties in measuring reliably circulating cytokine
concentrations have been extensively documented elsewhere, and
the relevance of such measurements must also be considered.
Local tissue cytokine production by inflammatory cells (or tumour
cells) is likely to be a better indicator of cytokine activity in cancer
cachexia (Falconer et al, 1994; Martignoni et al, 2005). However,
circulating acute-phase proteins (for example, CRP) remain robust
indices of systemic pro-inflammatory status.
The findings of this study suggest that processes other than
reduced food intake or mechanical obstruction alone are involved
in the nutritional decline in patients with gastro-oesophageal
malignancy. The realisation that weight loss in these patients may
be composed of more than one component can modify therapeutic
intervention. Recognition of the potential interactions between
systemic inflammation and cancer may inform the development of
appropriate therapeutic strategies to ameliorate weight loss,
making patients more tolerant to cancer-modifying therapies such
as surgery or chemotherapy (Fearon, 2008). It is also important to
consider that the relative importance of these components may
change during the course of an individual patient’s illness,
highlighting the need for periodic re-assessment and flexibility
in terms of nutritional and therapeutic intervention. In addition,
accelerated weight loss may provide one of the mechanisms by
which systemic inflammation acts to reduce survival duration in a
variety of different types of cancer (Falconer et al, 1995; Scott et al,
2002; Lamb et al, 2006; Deans et al, 2007).
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